Night Shift Doesn't Cause Breast Cancer : lifezette

As it stated in lifezette

Night Shift Doesn't Cause Breast Cancer

Night Shift Doesn't Cause Breast Cancer

There are any number of factors that may increase a woman's risk for breast cancer — but working the night shift isn't among them.Data from three new studies and from a review of currently available evidence indicate that night shift work has little or no effect on breast cancer incidence.The findings refute a 2007 assessment by the World Health Organization's International Agency for Research on Cancer (IARC) indicating that night shift work was probably carcinogenic.Related: Cancer Loves a Sitting DuckThe findings most likely also ease the minds of a lot of women who don't work typical business hours and who have felt for years that they were putting their health at risk.


by the same token on allure

Black Women and Breast Cancer Survival Rate

Black Women and Breast Cancer Survival Rate

Black women in the U.S. are more likely than white women to be diagnosed with breast cancer at a young age—and their risk of dying from the disease is 42 percent higher.Forty-two percent.The good news: The medical world is putting new focus on bringing that shocking number down.Shay Sharpe's left breast got incredibly itchy after she wore a new dress.


in the same way businesswire

Fulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer

Fulvestrant Demonstrates Progression-Free Survival Advantage in 1st Line Advanced Breast Cancer

WILMINGTON, Del.--(BUSINESS WIRE)--AstraZeneca today announced data from the Phase III FALCON trial demonstrating superior median progression-free survival (PFS) for fulvestrant 500mg compared to anastrozole 1mg in the 1st line treatment of postmenopausal women with locally-advanced or metastatic breast cancer, who have not had prior hormonal treatment for hormone receptor positive (HR+) breast cancer.1 The primary endpoint was PFS and the FALCON trial enrolled 462 patients.The results, announced at the 2016 European Society for Medical Oncology (ESMO) Congress, show that the median PFS was 2.8 months longer with fulvestrant than anastrozole (Hazard ratio 0.797; 95% confidence interval: 0.637-0.999; p=0.0486).The median PFS was 16.6 months in the fulvestrant arm, compared with 13.8 months in the anastrozole arm.1 Aromatase inhibitors, such as anastrozole, are the current standard of care in 1st line treatment for postmenopausal women with hormone-receptor positive (HR+) advanced breast cancer.2,3,4Professor Matthew Ellis, Principal Investigator of the FALCON trial, said: "These data document a benefit for fulvestrant in delaying disease progression as a 1st line therapy, an important goal for women with metastatic breast cancer.


not to mention shreveporttimes

October is National Breast Cancer awareness month

October is National Breast Cancer awareness month

Gary Calligas Senior Living Gary CalligasSince 1990 to 2013, studies have shown that breast cancer has had a 37% decline in mortality.This good news is as a result of science, education and direct help to people facing breast cancer.Nevertheless, breast cancer is still the leading cause of cancer death among women ages 20 to 59 in the United States.There are around 200,000 persons diagnosed with breast cancer and more than 40,000 deaths annually.


let alone 9news

Breast Cancer survivors dance to help patients

Breast Cancer survivors dance to help patients

KUSA - Cancer treatment can create a real financial hardship.This weekend a group of breast cancer survivors will be raising money to help other women fighting the disease.They'll do it by dancing.Michelle McGarry is a survivor.